Skip to main content

Table 1 Basic characteristics in distinct ABO blood type groups of patients with non-small cell lung cancer (NSCLC)

From: Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer: a retrospective analysis of 1601 cases at a single cancer center

Characteristic

ABO blood type

P valuea

O

A

B

AB

Total (cases)

627

443

425

106

 

Age

 Median (years)

59

59

59

59

 

 Range (years)

30–82

24–80

19–84

23–81

 

 <55 years [cases (%)]

156 (25.2)

135 (31.8)

207 (33.0)

32 (30.2)

0.11

 55–64 years [cases (%)]

137 (30.9)

171 (40.2)

239 (38.1)

43 (40.6)

 

 >64 years [cases (%)]

150 (33.9)

119 (28.0)

181 (28.9)

31 (29.2)

 

Sex [cases (%)]

    

0.20

 Males

451 (71.9)

329 (74.3)

297 (69.9)

81 (76.4)

 

 Females

176 (28.1)

114 (25.7)

128 (30.1)

25 (23.6)

 

ECOG PS score [cases (%)]

    

0.94

 0

305 (48.6)

211 (47.6)

199 (46.8)

52 (49.1)

 

 1

322 (51.4)

232 (52.4)

226 (53.2)

54 (50.9)

 

Smoking status [cases (%)]

    

0.21

 Never

243 (38.8)

177 (40.0)

185 (43.5)

37 (34.9)

 

 Former

74 (11.8)

59 (13.3)

35 (8.2)

13 (12.3)

 

 Current

310 (49.4)

207 (46.7)

205 (48.2)

56 (52.8)

 

Pathology [cases (%)]

    

0.67

 Squamous cell carcinoma

242 (38.6)

149 (33.6)

142 (33.4)

38 (35.8)

 

 Adenocarcinoma

327 (52.2)

256 (57.8)

250 (58.8)

58 (54.7)

 

 Adenosquamous carcinoma

41 (6.5)

24 (5.4)

21 (4.9)

7 (6.6)

 

 Others

17 (2.8)

14 (3.2)

12 (2.8)

3 (1.8)

 

pT category [cases (%)]

    

0.80

 1

112 (17.9)

81 (18.3)

68 (16.0)

17 (16.0)

 

 2

393 (62.7)

274 (61.9)

288 (67.8)

68 (64.2)

 

 3

70 (11.2)

50 (11.3)

43 (10.1)

14 (13.2)

 

 4

52 (8.3)

38 (8.6)

26 (6.1)

7 (6.6)

 

pN category [cases (%)]

    

0.62

 0

372 (59.3)

239 (54.0)

232 (54.6)

62 (58.5)

 

 1

77 (12.3)

60 (13.5)

62 (14.6)

14 (13.2)

 

 2

178 (28.4)

144 (32.5)

131 (30.8)

30 (28.3)

 

pTNM stage [cases (%)]

    

0.88

 Ia

80 (12.8)

58 (13.1)

52 (12.2)

13 (12.3)

 

 Ib

231 (36.8)

144 (32.5)

155 (36.5)

37 (34.9)

 

 IIa

18 (2.9)

11 (2.5)

10 (2.4)

1 (0.9)

 

 IIb

91 (14.5)

62 (14.0)

59 (13.9)

20 (18.9)

 

 IIIa

207 (33.0)

168 (37.9)

149 (35.0)

35 (33.0)

 

Surgery type [cases (%)]

    

0.97

 Lobectomy

506 (80.7)

356 (80.4)

344 (80.9)

87 (82.1)

 

 Pneumonectomy

96 (15.3)

66 (14.9)

67 (15.8)

15 (14.2)

 

 Others

25 (4.0)

21 (4.7)

14 (3.3)

4 (3.7)

 

Chemotherapy [cases (%)]

    

0.81

 Neoadjuvant + adjuvant

14 (2.2)

13 (2.9)

13 (3.1)

3 (2.8)

 

 Neoadjuvant only

19 (3.0)

11 (2.5)

11 (2.6)

6 (5.7)

 

 Adjuvant only

389 (62.0)

287 (64.8)

272 (64.0)

66 (62.3)

 

 No

205 (32.7)

132 (29.8)

129 (30.4)

31 (29.2)

 
  1. ECOG PS Eastern Cooperative Oncology Group performance status, pT category pathologic tumor category, pN category pathologic node category, pTNM stage pathologic tumor-node-metastasis stage
  2. aχ2 test (multigroup comparison)
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us